Contact this trialFirst, we need to learn more about you.
SAR440894 for Chikungunya Fever
Recruiting0 awardsPhase 1
Austin, Texas
This trial will test the safety of a new drug, SAR440894, given to healthy adults aged 18-45 in ascending doses. There will be five cohorts of 8 subjects each, 6 receiving the drug and 2 receiving placebo, and 2 sentinel subjects who will be dosed first. The trial will last approximately 150 days.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.